摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Hydroxy-6-(benzoyl)hexanamide

中文名称
——
中文别名
——
英文名称
N-Hydroxy-6-(benzoyl)hexanamide
英文别名
N-hydroxy-7-oxo-7-phenylheptanamide
N-Hydroxy-6-(benzoyl)hexanamide化学式
CAS
——
化学式
C13H17NO3
mdl
——
分子量
235.283
InChiKey
IHUNPXAEVKBAPH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    66.4
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors
    摘要:
    A series of new, structurally simple trichostatin A (TSA)-like straight chain hydroxamates were prepared and evaluated for their ability to inhibit partially purified human histone deacetylase 1 (HDAC-1). Some of these compounds such as 8m, 8n, 12, and 15b exhibited potent HDAC inhibitory activity with low nanomolar IC50 values, comparable to natural TSA. These compounds induce hyperacetylation of histones in T24 human cancer cells and significantly inhibit proliferation in. various human cancer cells. They also induce expression of p21 and cause cell cycle blocks in human cancer cells. in this paper, we describe the synthesis of these new compounds as well as structure-activity relationship results from enzyme inhibition and alterations in cellular function.
    DOI:
    10.1021/jm020154k
点击查看最新优质反应信息

文献信息

  • Inhibitors of histone deacetylase
    申请人:——
    公开号:US20020115826A1
    公开(公告)日:2002-08-22
    The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了用于抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和状况的组合物和方法。
  • Inhibitors of Histone Deacetylase
    申请人:Delorme Daniel
    公开号:US20090181971A1
    公开(公告)日:2009-07-16
    The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病状的组合物和方法。
  • INHIBITORS OF HISTONE DEACETYLASE
    申请人:Methylgene, Inc.
    公开号:EP1280764B1
    公开(公告)日:2010-11-24
  • METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR
    申请人:Yu Qiang
    公开号:US20110053882A1
    公开(公告)日:2011-03-03
    The invention relates to a method of preventing, inhibiting, arresting or reversing tumourigenesis in a cell as well as a method of inducing apoptosis in a tumour cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also provided is a pharmaceutical composition that comprises a compound of general formula (I), wherein A is CH or N, R 1 , R 4 and R 5 are independent from each other H, an aliphatic group, an alicyclic group, an aromatic group, an arylaliphatic group, and an arylalicyclic group comprising 0-3 heteroatoms. The heteroatoms may be N, O, S, or Si. R 4 and R 5 may optionally be linked so as to define an aliphatic hydrocarbyl bridge. R 2 is H or a halogen such as F, Cl, Br or L. R 3 is H, F, Cl or an aliphatic or arylaliphatic group that includes 1-8 main chain carbon atoms and 0-3 heteroatoms. The pharmaceutical composition also comprises a histone deacetylase inhibitor.
  • US7288567B2
    申请人:——
    公开号:US7288567B2
    公开(公告)日:2007-10-30
查看更多